[1] LiawYF , LeungN , GuanR , etal.Asian-PacificconsensusstatementonthemanagementofchronichepatitisB :anupdate[J].JGastroenterolHepatol, 2003, 18∶239-245.
|
[2]姚光弼, 王宝恩, 崔振宇, 等.拉米夫定治疗慢性乙型肝炎三年疗效观察[J], 中华内科杂志, 2003, 42∶383-387.
|
[3]拉米夫定临床应用专家指导小组.2000年拉米夫定临床应用指导意见[J].中华肝脏病杂志, 2000, 8∶249-250.
|
[4] 拉米夫定临床应用专家指导小组.2003年拉米夫定临床应用专家共识[J].中华传染病杂志, 2003, 21∶301-304.
|
[5] TheEASLJury.EASLinternationalconsensusconferenceonhepatitisB[J].JHepatol, 2003, 38∶533-540.
|
[6] LokAS , McMahonBJ.ChronichepatitisB[J].Hepatology, 2001, 34∶1225-1241.
|
[7] LiLL , ChunTW , YinML , etal.Prophylacticlamivudinepreventshep atitisBreactivationandmortalityinpatientsreceivingimmunosuppressionandchemotherapy[J].Hepatology, 2000, 32 (Pt2) ∶1183.
|
[8] LiawYF , SungJJY .ChowWC .etal.EffectsoflamivudineondiseaseprogressionanddevelopmentoflivercancerinadvancedchronichepatitisB :aprospectivedouble-blinedplacebo-controlledclinicaltrial[J].Hepatology, 2003, 38 (Suppl) 1∶262A .
|
[9] FontanaRJ.MangementofpatientswithdecompensatedHBVcirrhosis[J].Seminarsinliverdisease.2003, 23∶89-100.
|
[10] HomX , LittleNR , GardnerSD , etal.PredictorsofvirologicresponsetoLamivudinetreatmentinchildrenwithchronichepatitisBinfection[J].PediatrInfectDisJ, 2004, 23∶441-445.
|
[11] JonasMM , KelleyDA , MizerskiJ , etal.ClinictrialoflamivudineinchildrenwithchronichepatitisB[J].NEngJMed, 2002, 346∶1706-1713.
|
[12] SokalEM .DrugtreatmentofpediatricchronichepatitisB[J].PaediatrDrugs.2002, 4∶361-369.
|
[13]姚光弼, 崔振宇, 姚集鲁, 等.国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验[J].中华肝脏病杂志, 2003, 11∶103-108.
|
[14] DienstagJL , CianciaraJ, KarayalcinS , etal.DurabilityofserologicresponseafterlamivudinetreatmentofchronichepatitisB[J].Hepatolo gy, 2003, 37∶748-755.
|
[15] SchiffER , LaiCL , HadziyannisS , etal.Adefovirdipivoxiltherapyforlamivudine-resistanthepatitisBinpre-andpost-livertransplan-tationpatients[J].Hepatology, 2003, 38∶1419-1427.
|
[16] LiawYF , LeungNW , ChangTT , etal.EffectsofextendedlamivudinetherapyinAsianpatientswithchronichepatitisB[J].Gastroenterology, 2000, 119∶172-180.
|
[17] ChangTT , LaiCL , LiawYF , etal.IncrementalincreasesinHBeAgseroconversionandcontinuedALTnormalizationinAsianchronicHBV (CHB) patientstreatedwithlamivudineforfouryears[J].AntiviralTherapy, 2000, 5 (Suppl1) ∶44.
|
[18] SongBC , SuhDJ, LeeHC , etal.HepatitisBeantigenseroconversionafterlamivudinetherapyisnotdurableinpatientswithchronichepatitisBinKorea[J].Hepatology, 2000, 32∶803-806.
|
[19] HonkoopP , deManRA , NiestersHG , etal.AcuteexacerbationofchronichepatitisBvirusinfectionafterwithdrawaloflamivudinetherapy[J].Hepatology, 2000, 32∶635-639.
|
[20] KobayashiS , IdeT , SataM , etal.DetectionofYMDDmotifmutationsinsomelamivudine-untreatedasymptomatichepatitisBviruscarriers[J].JHepatol, 2001, 34∶584-586.
|
[21]KirishimaT , OkanoueT , DaimonY , etal.DetectionofYMDDmutantusinganovelsensitivemethodinchronicliverdiseasetypeBpatientsbe foreandduringlamivudinetreatment[J].JHepatol, 2002, 37∶259-265.
|
[22] ZhangXX , LiuCM , GongQM , etal.Evolutionofwildtypeandmu tantsoftheYMDDmotifofhepatitisBviruspolymeraseduringlamivudinetherapy[J].JGastroenteroloHepatolo, 2003, 1353-1357.
|
[23] SchalmSW , HeathcoteJ, CianciaraJ , etal.Lamivudineandalphain terferoncombinationtreatmentofpatientswithchronichepatitisBinfec tion:arandomisedtrial[J].Gut, 2000, 46∶562-568.
|
[24] MariaButi, RafaelEsteban.Entecavir, FTC , L -RMAU , LdTandothers[J].JHepatol, 2003, 39∶S139-S142.
|